Tian Zhang, MD, MHS summaries the frontline systemic therapy for mRCC session from #UromigosLive . Link to full session here:

guoncologynow.com/post/the-uromi…

Sumanta Pal Shilpa Gupta Neeraj Agarwal Tom Powles Brian Rini, MD

Cora Sternberg describes her recent trial with FGFR inhibition vs chemotherapy in FGFR selected patients with platinum refractory UC Cora Sternberg Brian Rini, MD anchor.fm/the-uromigos/e…

Axel Bex summarizes the #UromigosLive perioperative RCC session. Full session available here:
guoncologynow.com/post/the-uromi…

Sumanta Pal Neeraj Agarwal Shilpa Gupta Tian Zhang, MD, MHS Tom Powles Brian Rini, MD

Defining who benefits from adding docetaxel to ADT/ARTA or RT to the primary needs additonal evidence. #BSPOKE and ProBio will help answer this question. And let's stay curious and don't try to give the answer upfront Piet Ost Chris Parker Christopher Sweeney, MBBS Uromigos AttardLab

Thanks to Uromigos GU Oncology Now Tom Powles Brian Rini, MD for putting together such a thought provoking and timely discussion on the future of #bladdercancer clinical drug development. A fresh and engaging approach to medical education from these innovators.

Always great to hear Jonathan Rosenberg MD discussing his important contributions to #bladdercancer #UromigosLive

#UromigosLive Uromigos #Bladdercancer Where do we stand with VEGG targeted therapies in UC.
May have a role in maintenance setting.
#MAINCAV trial cabo-avelumab

Brian Rini, MD Tom Powles Jonathan Rosenberg MD Matt Galsky Petros Grivas KSridhar

What a grand finale to the amazingly innovative #UromigosLive organized by Brian Rini, MD Tom Powles Uromigos Fun, music, superb food and mind stimulating discussions on GU controversies from fantastic colleagues & friends! Jonathan Rosenberg MD Dan George Sumanta Pal Neeraj Agarwal

Adjuvant nivolumab in bladder cancer for everyone, some or none? #UromigosLive Petros Grivas

💡 #UromigosLive #kidneycancer
✅Panelists Tian Zhang, MD, MHS #AxelBex Tom Powles #DavidMcDermott highlight the importance of 1⃣ discussing outcomes of available adjuvant trials w patients & 2⃣ personalizing strategies based on pt preferences re DFS benefit vs risk for toxicities.

Adjuvant therapy in renal cancer. Where we are now and what’s next? Sumanta Pal #UromigosLive #nashville22

Why has the control arm am of the Vision trial (Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer) attracted controversy and is it justified? Michael Morris #UromigosLive

Hard to sum up in <2 min the rich dialogue we had re: adj tx at #UromigosLive . Brian Rini, MD moderated w some heated debate between Tom Powles & #DavidMcDermott . Lots of fun when we all (incl #AxelBex & Tian Zhang, MD, MHS) predicted future adj trials. See full webcast on YouTube!

#UromigosLive #KidneyCancer
Brian Rini, MD asks what’s the most exciting trial of future?
Sumanta Pal CD70 CART-cells
Tian Zhang, MD, MHS CD-70 pathway
#DavidMcDermott -TIL tx
HIF-2 a, CDK4/6 inhibitors ?
Tom Powles

Gold or garbage?

Enfortumab vedotin and pembrolizumab vs enfortumab vedotin in cisplatin ineligible 1st line UC. Is it enough for FDA approval? Will we need to wait for EV302? #nashville22 Jonathan Rosenberg MD

3-y FUP update of #PURE01 . RFS/EFS confirm early positive data, w potential benefit across ypTN categories. Giuseppe_Basile MD_Bandini Uni San Raffaele Ospedale San Raffaele aacrjournals.org/clincancerres/…

Adjuvant nivolumab in bladder cancer for everyone, some or none? #UromigosLive Petros Grivas